SEER*DMS MU2 Workgroup Year2 Objectives

Introduction

State registries are receiving request from physician offices who would like to start electronically reporting their cancer encounters through Cancer Reporting objective of the Meaningful Use Initiative. The objective of this workgroup is to work with IMS to develop a workflow for processing these electronic reports within SEER*DMS. Up until this point IMS has added support in SEER*DMS to load these types of reports, allow them to match at a patient level, and allow the user to view the data. Over the next 10 months the workgroup hopes to complete the below objectives.

Data Analysis

- Analysis of the current CDA messages each registry has received.
- Data can be grouped into 2 categories:
 - o CDA not matching an existing patient set
 - How many truly new cases are found?
 - CDA matching an existing patient set
 - How many new CTC's were found?
 - How many matched existing CTCs?
 - If matched an existing CTC, how many provided new Tx?
 - For Patient Sets with multiple CDA per CTC:
 - Are the CDAs true duplicates?
 - Does the last CDA contain all the data for the previous with the new info appended?
 - Implementation guide states new records should contain previous cda data
 - o Data quality?
 - o Create template for all registries to use

Use Cases

- Current Use Cases
 - Update Follow Up info (including other demographic fields)
 - o CaseFinding
 - Additional Tx
 - o Rapid case ascertainment
 - Mets or Recurrence or Comorbidities
- Are there any more Use Cases for CDA data?
- Develop a workflow for each Use Case

Interface Development

- Analysis of the current methods for viewing the CDA data in DMS
- What interface is best for viewing the data in DMS?
- What fields do the users need to see?
- What fields can be removed?

Priority Timeline

- Present Year End
 - o Data Analysis
- Jan 2018 April 2018
 - o Use Case (Update Fup info, Casefinding) Workflow Development
 - o Interface Analysis Development
- May 2018 forward
 - Use Case (Additional Tx, RCA, Mets or Recurrence or Comorbidities) Workflow Development